External quality assessment for epidermal growth factor receptor gene mutation determination in Shanghai

doi:10.3969/j.issn.1673-8640.2017.011.026

Abstract

Abstract:

Objective To evaluate the external quality assessment（EQA） performance for epidermal growth factor receptor（EGFR） gene mutation determination in Shanghai,and to discuss and solve the problems in clinical laboratories in order to improve determination quality. Methods EQA program for EGFR determination was set twice a year. Each sample panel of 2016 EQA program contained 5 samples. The participating laboratories were asked to report their results before deadline. The scores of EQA and the overall coincidence rate of each sample were calculated. The overall coincidence rate of positive samples and negative ones were also calculated. Results In 2016,25 and 30 valid laboratory results were received. Totally,20（80%）and 26（87%）laboratories submitted correct results for all samples,and the EQA score of 0（0%） and 1（3%） laboratory was <80. The highest coincidence rate of the samples was 100%,and the lowest rate was 88%. The overall coincidence rates of positive samples and negative ones were 95.76% and 97.27%,respectively. Missed determination in composite mutation samples was a major cause for inconsistency,which was up to 50%（5/10）. Conclusions The results of 2016 EQA program suggest that the overall coincidence rate of laboratories enrolled is high,while there exists problems in some laboratories. Missed determination in composite mutation samples is a major cause for inconsistency. Quality control in clinical laboratories is essential to assure accuracy of results.

Key words: Epidermal growth factor receptor, Gene mutation, External quality assessment

CLC Number:

R446.1

JIANG Lingli, XIAO Yanqun, WANG Xueliang, BAO Yun, YANG Yixiao, WANG Hualiang. External quality assessment for epidermal growth factor receptor gene mutation determination in Shanghai[J]. Laboratory Medicine, 2017, 32(11): 1055-1058.

Figures/Tables 2

References 7

[1]	HERBST R S,FUKUOKA M,BASELGA J.Gefitinib-a novel targeted approach to treating cancer[J]. Nat Rev Cancer,2004,4(12):956-965.
[2]	张蓉,陈薇雅,甘洁民,等. EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析[J]. 检验医学,2013,28(6):506-510.
[3]	石远凯,孙燕,于金明,等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志,2016,19(1):1-15.
[4]	TANAKA T,MATSUOKA M,SUTANI A,et al.Frequency of and variables associated with the EGFR mutation and its subtypes[J]. Int J Cancer,2010,126(3):651-655.
[5]	VAN KRIEKEN J H,SIEBERS A G,NORMANNO N,et al. European consensus conference for external quality assessment in molecular pathology[J]. Ann Oncol,2013,24(8):1958-1963.
[6]	PATTON S,NORMANNO N, BLACKHALL F,et al.Assessing standardization of molecular testing for non-small-cell lung cancer:results of a worldwide external quality assessment(EQA) scheme for EGFR mutation testing[J]. Br J Cancer,2014,111(2):413-420.
[7]	韩彦熙,张瑞,李金明. 2014年中国KRAS基因突变检测室间质量评价[J]. 中华检验医学杂志,2015,38(10):661-665.

方法	100分		80分		<80分
方法	第1次（25家）	第2次（30家）	第1次（25家）	第2次（30家）	第1次（25家）	第2次（30家）
ARMS	17	22	4	2	0	1
实时荧光PCR	3	3	1	0	0	0
Sanger测序	0	0	0	1	0	0
其他	0	1	0	0	0	0
合计（%）	20（80.00）	26（86.67）	5（20.00）	3（10.00）	0（0.00）	1（3.33）

方法	100分		80分		<80分
方法	第1次（25家）	第2次（30家）	第1次（25家）	第2次（30家）	第1次（25家）	第2次（30家）
ARMS	17	22	4	2	0	1
实时荧光PCR	3	3	1	0	0	0
Sanger测序	0	0	0	1	0	0
其他	0	1	0	0	0	0
合计（%）	20（80.00）	26（86.67）	5（20.00）	3（10.00）	0（0.00）	1（3.33）

样本号	预期基因型	结果符合实验室数	符合率（%）
第1次EQA
1621	L858R+T790M	22	88
1622	野生型	24	96
1623	19del	25	100
1624	L858R	24	96
1625	野生型	25	100
第2次EQA
1631	L858R	29	97
1632	19del	30	100
1633	L858R+T790M	28	93
1634	野生型	30	100
1635	野生型	28	93

样本号	预期基因型	结果符合实验室数	符合率（%）
第1次EQA
1621	L858R+T790M	22	88
1622	野生型	24	96
1623	19del	25	100
1624	L858R	24	96
1625	野生型	25	100
第2次EQA
1631	L858R	29	97
1632	19del	30	100
1633	L858R+T790M	28	93
1634	野生型	30	100
1635	野生型	28	93

[1]	YAO Ling, GAO Chunyan, LIU Minglei. Virulence characteristics of Streptococcus pneumoniae，PBP gene mutation and β-lactam resistance [J]. Laboratory Medicine, 2025, 40(5): 450-454.
[2]	BAO Yun, YU Tingting, QUAN Jing, YIN Liufan, ZHANG Pengyin, XIAO Yanqun. Result analysis of external quality assessment of next-generation sequencing for genetic testing of inherited diseases in Shanghai [J]. Laboratory Medicine, 2025, 40(2): 160-164.
[3]	ZHOU Jiakuan, GUO Ping, CAI Qi, YANG Mingkang, HUANG Zhixi, XUE Yilun, HUA Renxiang, LIN Han, LI Jiaming, WANG Jianbiao. Molecular epidemiological analysis of patients with increased stomatocytes and giant platelets in peripheral blood [J]. Laboratory Medicine, 2025, 40(2): 171-177.
[4]	TANG Jiemei, WANG Binbin, LIU Na, TANG Gusheng. Influence of concomitant gene mutation on acute myeloid leukemia patients with RUNX1::RUNX1T1 fusion [J]. Laboratory Medicine, 2025, 40(2): 186-191.
[5]	LIU Yang, HE Chengshan, JIANG Xiudi, LU Zhicheng. HBV PreS/S region gene mutation inducing hepatocyte endoplasmic reticulum stress causing hepatocellular carcinoma [J]. Laboratory Medicine, 2024, 39(12): 1229-1233.
[6]	ZHAO Qiang, XU Xiuwen, HAN Jiaojiao, SONG Ying, MIAO Yingbo, ZHU Peichao, ZHOU Wei, LIN Shiyang, TONG Lanfei, CHE Yiming, JIN Lei, XU Chong. Effect of different preservation methods on stability of samples in external quality assessment of paroxysmal nocturnal hemoglobinuria by flow cytometry [J]. Laboratory Medicine, 2024, 39(11): 1048-1052.
[7]	YANG Xue, ZHU Jun, JIANG Lingli, WANG Qing, HU Xiaobo. Evaluation on the consistency of blind sample test results of 9 SARS-CoV-2 nucleic acid determination kits in Shanghai，China [J]. Laboratory Medicine, 2023, 38(8): 776-780.
[8]	ZHANG Weimin, LI Ting, ZHANG Chen, XIE Nan, ZHAO Fei, WU Xia, MENG Qinghao, LI Min, GAO Xuan, YANG Sijie. Role of Youden plot in external quality assessment of sperm concentration [J]. Laboratory Medicine, 2023, 38(2): 167-171.
[9]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[10]	CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341.
[11]	CHEN Yuemei, JIN Yongmei, ZENG Tingting, JIANG Nenggang, LIAO Hongyan. Diagnosis and clinical characteristics of acute myeloid leukemia with BCR-ABL1 accompanied by FLT3-ITD and multiple gene mutations [J]. Laboratory Medicine, 2022, 37(4): 365-369.
[12]	DENG Shanying, PEI Yuqing, ZHANG Chunying, XIE Heng, MENG Qiang, MA Ying. Analysis of external quality assessment of parasite morphology from 2013 to 2020 in West China Hospital of Sichuan University [J]. Laboratory Medicine, 2022, 37(2): 188-193.
[13]	YANG Xue, JU Yi, OU Yuanzhu, ZHU Yuqing, XU Chong, JIANG Lingli, WANG Qing, ZHOU Jing. Analysis on the results of external quality assessment of mutual recognition quantitative items in Shanghai [J]. Laboratory Medicine, 2022, 37(12): 1129-1134.
[14]	MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46.
[15]	ZHANG Pengyin, QUAN Jing, WANG Xueliang, XIAO Yanqun, BAO Yun. External quality assessment of irinotecan-related metabolism genotyping in Shanghai [J]. Laboratory Medicine, 2021, 36(8): 875-879.